Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-006966
Filing Date
2025-05-08
Accepted
2025-05-08 16:06:05
Documents
86
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20250331x10q.htm   iXBRL 10-Q 1836519
2 EX-31.1 crvs-20250331xex31d1.htm EX-31.1 11792
3 EX-31.2 crvs-20250331xex31d2.htm EX-31.2 11730
4 EX-32.1 crvs-20250331xex32d1.htm EX-32.1 11702
5 GRAPHIC crvs-20250331x10q008.jpg GRAPHIC 38557
  Complete submission text file 0001558370-25-006966.txt   7952161

Data Files

Seq Description Document Type Size
6 EX-101.SCH crvs-20250331.xsd EX-101.SCH 42924
7 EX-101.CAL crvs-20250331_cal.xml EX-101.CAL 45902
8 EX-101.DEF crvs-20250331_def.xml EX-101.DEF 218159
9 EX-101.LAB crvs-20250331_lab.xml EX-101.LAB 406355
10 EX-101.PRE crvs-20250331_pre.xml EX-101.PRE 363559
89 EXTRACTED XBRL INSTANCE DOCUMENT crvs-20250331x10q_htm.xml XML 1338966
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 25925971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)